Pathos AI raises $237M Series E at $3B valuation
Pathos AI, a biotech startup using AI to develop oncology drugs, raised a $237 million Series E round at a $3 billion post-money valuation. That is up from a $1.6 billion valuation in May 2025.
- Series E round brought Pathos AI $237M
- Post-money valuation reached $3B
- Valuation was $1.6B in May 2025
- Startup uses AI to develop oncology drugs
Read next
Business